University of Birmingham Centre of Cardiovascular Sciences, City Hospital, Birmingham, England, UK.
Curr Vasc Pharmacol. 2010 Nov;8(6):775-9. doi: 10.2174/157016110793563834.
Malignant hypertension (MHT) is the most severe form of hypertension which is clinically defined as the presence of high blood pressure in association with bilateral retinal haemorrhages and/or exudates, with or without papilloedema. The aim of this review article is to discuss whether MHT is a problem which is truly becoming a rarity, or is it simply a problem with underdiagnosis. Despite the improvements in the general management of hypertension, we have no strong evidence of a declining incidence of MHT. In contrast, this disorder may appear to become even more common worldwide taking into account the growing hypertensive population in the developing countries. Although the diagnostic criteria of MHT appear to be simple and straightforward, the prompt diagnose of MHT may be difficult in substantial proportion of patients who often present with clinical symptoms only at a late stage of irreversible target organ changes. Furthermore, MHT and the accompanying ocular changes may gradually resolve making retrospective diagnosis problematic, whilst persistent target organ damage can drive the development of complications and have a negative prognosis in these patients. Clearly, MHT should not yet be forgotten nor ignored by clinicians.
恶性高血压(MHT)是最严重的高血压形式,临床上定义为伴有双侧视网膜出血和/或渗出,伴有或不伴有视盘水肿的高血压。本文的目的是讨论 MHT 是否真的变得罕见,还是仅仅是诊断不足的问题。尽管高血压的一般治疗有所改善,但我们没有强有力的证据表明 MHT 的发病率正在下降。相反,考虑到发展中国家高血压患者人数的增加,这种疾病在全球范围内可能变得更加普遍。尽管 MHT 的诊断标准似乎简单明了,但在很大比例的患者中,MHT 的及时诊断可能很困难,这些患者通常仅在不可逆靶器官改变的晚期才出现临床症状。此外,MHT 及其伴随的眼部改变可能逐渐消退,使得回顾性诊断变得困难,而持续的靶器官损伤可能导致并发症的发展,并对这些患者产生不利的预后。显然,MHT 不应被临床医生遗忘或忽视。